Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. - Sorbonne Université Access content directly
Journal Articles British Journal of Cancer Year : 2008

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.

M. J. Mckeage
  • Function : Author
J. von Pawel
  • Function : Author
M. Reck
  • Function : Author
M. B. Jameson
  • Function : Author
M. A. Rosenthal
  • Function : Author
R. Sullivan
  • Function : Author
D. Gibbs
  • Function : Author
P. N. Mainwaring
  • Function : Author
M. Serke
  • Function : Author
Jérôme Lafitte
  • Function : Author
L. Freitag
  • Function : Author
E. Quoix
  • Function : Author

Abstract

ASA404 (5,6-dimethylxanthenone-4-acetic acid or DMXAA) is a small-molecule tumour-vascular disrupting agent (Tumour-VDA). This randomised phase II study evaluated ASA404 plus standard therapy of carboplatin and paclitaxel in patients with histologically confirmed stage IIIb or IV non-small cell lung cancer (NSCLC) not previously treated with chemotherapy. Patients were randomised to receive

Dates and versions

hal-00597060 , version 1 (31-05-2011)

Identifiers

Cite

M. J. Mckeage, J. von Pawel, M. Reck, M. B. Jameson, M. A. Rosenthal, et al.. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.. British Journal of Cancer, 2008, 99 (12), pp.2006-12. ⟨10.1038/sj.bjc.6604808⟩. ⟨hal-00597060⟩
15 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More